In their bid to find the best combination of therapies to
treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.
Brentuximab vedotin was previously approved by the FDA to
treat cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic
anaplastic large cell lymphoma (ALCL) after failure of other treatment, and primary cutaneous ALCL after failure of other treatment.